Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 474

Sort by

Sort Order Select

Journal Articles

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Blood (2021) 137 (15): 2070–2084.

https://doi.org/10.1182/blood.2019004509

Published: 2021

Includes: Supplemental data

Journal Articles

Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia–like IBMFS ADH5/ALDH2 deficiency

Anfeng Mu, Asuka Hira, Akira Niwa, Mitsujiro Osawa, Kenichi Yoshida, Minako Mori, Yusuke Okamoto, Kazuko Inoue, Keita Kondo, Masato T. Kanemaki, Tomonari Matsuda, Etsuro Ito, Seiji Kojima, Tatsutoshi Nakahata, Seishi Ogawa, Keigo Tanaka, Keitaro Matsuo, Megumu K. Saito, Minoru Takata

Blood (2021) 137 (15): 2021–2032.

https://doi.org/10.1182/blood.2020009111

Published: 2021

Includes: Supplemental data

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Elucidating an Essential Role of Promoting Endothelial-to-Hematopoietic Transition By a Key EMT-Regulator ZEB2 Using a Human iPSC-Based Model

Mengyao Wu, Senquan Liu, Linzhao Cheng, PhD, Tong Chen, MD

Blood (2019) 134 (Supplement_1): 3716.

https://doi.org/10.1182/blood-2019-126908

Published: 2019

Journal Articles

Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

Rebecca Soto, BS, Edroaldo Lummertz da rocha, PhD, Linda T Vo, PhD, Mariam Hachimi, PhD, Jenna M Frame, PhD, Paul J. Wrighton, PhD, Wolfram Goessling, MD PhD, George Q. Daley, MD PhD, Trista E North, PhD

Blood (2019) 134 (Supplement_1): 3710.

https://doi.org/10.1182/blood-2019-131464

Published: 2019

Journal Articles

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Carissa Dege, PhD, Katherine H Fegan, MS, J Philip Creamer, IV, BA,BS, Melissa M Berrien-Elliott, PhD, Stephanie A. Luff, PhD, Julia A Wagner, PhD, Paul D. Kingsley, PhD, Kathleen E. McGrath, PhD, Todd A Fehniger, MD PhD, James Palis, MD, Christopher M. Sturgeon, PhD

Blood (2019) 134 (Supplement_1): 2464.

https://doi.org/10.1182/blood-2019-130347

Published: 2019

Journal Articles

Disease Modeling and Phenotype Rescue Using Inducible Pluripotent Stem Cells from Patients with Diamond-Blackfan Anemia

Senthil Velan Bhoopalan, MD PhD, Min-Joon Han, PhD, Steven Ellis, PhD, Harry Lesmana, MD, Jeremie H. Estepp, MD, Yoonjeong Jang, DVM,PhD, Mitchell J. Weiss, MD PhD, Marcin W. Wlodarski, MD PhD

Blood (2019) 134 (Supplement_1): 2496.

https://doi.org/10.1182/blood-2019-131354

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage

Blood (2019) 134 (Supplement_1): 4219.

https://doi.org/10.1182/blood-2019-126981

Published: 2019

Journal Articles

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

Tellechea Maria Florencia, MSc, Flavia S. Donaires, PhD, Tiago C. Silva, PhD, Lilian F. Moreira, PhD, Yordanka Armenteros, PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2500.

https://doi.org/10.1182/blood-2019-127466

Published: 2019

Journal Articles

SOX17 Is Essential for Integration of Arterial and HOXA Programs in Hemogenic Endothelium

Ho Sun Jung, Gene I. Uenishi, PhD, Mi Ae Park, PhD, Peng Liu, PhD, Matthew Raymond, James Thomson, Irene Ong, Igor Slukvin, MD PhD

Blood (2019) 134 (Supplement_1): 2476.

https://doi.org/10.1182/blood-2019-130789

Published: 2019

Journal Articles

Recreation of t(7;12)(q36;p13) in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9 Generates a Useful Model for Studying Acute Myeloid Leukemia

Tina Nilsson, MSc, BSc, Ahmed Waraky, PhD MSc, BSc, Anders Östlund, MSc, BSc, Laleh Arabanian, PhD, Julia Asp, PhD, Linda Fogelstrand, Lars Palmqvist, MD PhD

Blood (2019) 134 (Supplement_1): 2736.

https://doi.org/10.1182/blood-2019-123004

Published: 2019

Journal Articles

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2738.

https://doi.org/10.1182/blood-2019-130934

Published: 2019

Journal Articles

Adamts13-Cultured Red Blood Cells to Treat Thrombotic Thrombocytopenic Purpura

Kai Wang, PhD, Khulan Batbayar, PhD, Karl Roberts, Emmanuel Olivier, PhD, Eric E. Bouhassira, PhD

Blood (2019) 134 (Supplement_1): 89.

https://doi.org/10.1182/blood-2019-131929

Published: 2019

Journal Articles

Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells

Taylor B. Collins, Stephanie A. Luff, PhD, Luis F.Z. Batista, PhD, Christopher M. Sturgeon, PhD, Stephen T. Oh, MD

Blood (2019) 134 (Supplement_1): 2971.

https://doi.org/10.1182/blood-2019-130541

Published: 2019

Journal Articles

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Misaki Sugai, BS, Yu Abe, PhD, Yusuke Azami, MD, Yukari Yanai, MS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2019) 134 (Supplement_1): 3057.

https://doi.org/10.1182/blood-2019-122344

Published: 2019

Journal Articles

Harnessing a Novel Dyrk1a-Ablim2-MKL1 Regulatory Module in Megakaryocyte Morphogenesis to Enable Scalable Platelet "Pharming"

Kamaleldin E Elagib, PhDMBBS, Ashton Brock, PhD, Goar Mosoyan, Cara Clementelli, Lorrie L Delehanty, BS, Alexandra Pacheco-Benichou, Corinne Fruit, Thierry Besson, PhD, Stephen Morris, MD, Koji Eto, MD, Camelia Iancu-Rubin, PhD, Adam N Goldfarb, MD

Blood (2019) 134 (Supplement_1): 3250.

https://doi.org/10.1182/blood-2019-129049

Published: 2019

Journal Articles

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Jode P Goodridge, PhD, Sajid Mahmood, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Jason Dinella, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Uta Hopken, Armin Rehm, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 3214.

https://doi.org/10.1182/blood-2019-131373

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

Adenylate Kinase 2 Links Energy Metabolism and Cell Fate in Hematopoietic Stem and Progenitor Cells

Wenqing Wang, PhD, Avni Awani, PhD, Andrew Devilbiss, PhD, Thomas Mathews, PhD, Daniel Thomas, MD PhD, Daniel P. Dever, PhD, Matthew Porteus, MD PhD, Sean Morrison, PhD, Katja G Weinacht, MD PhD

Blood (2019) 134 (Supplement_1): 3705.

https://doi.org/10.1182/blood-2019-129424

Published: 2019

NARROW

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia–like IBMFS ADH5/ALDH2 deficiency

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Elucidating an Essential Role of Promoting Endothelial-to-Hematopoietic Transition By a Key EMT-Regulator ZEB2 Using a Human iPSC-Based Model

Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Disease Modeling and Phenotype Rescue Using Inducible Pluripotent Stem Cells from Patients with Diamond-Blackfan Anemia

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

SOX17 Is Essential for Integration of Arterial and HOXA Programs in Hemogenic Endothelium

Recreation of t(7;12)(q36;p13) in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9 Generates a Useful Model for Studying Acute Myeloid Leukemia

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Adamts13-Cultured Red Blood Cells to Treat Thrombotic Thrombocytopenic Purpura

Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Harnessing a Novel Dyrk1a-Ablim2-MKL1 Regulatory Module in Megakaryocyte Morphogenesis to Enable Scalable Platelet "Pharming"

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Adenylate Kinase 2 Links Energy Metabolism and Cell Fate in Hematopoietic Stem and Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only